Literature DB >> 25531173

Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation.

Hae Won Kim1, Jie-Hyun Kim, Ik Jae Lee, Jun Won Kim, Yong Chan Lee, Chang Geol Lee, Jae Jun Park, Young Hoon Youn, Hyojin Park.   

Abstract

BACKGROUND/AIM: Little is known about the patterns of treatment failure following definitive chemoradiotherapy (CCRT), especially in esophageal squamous cell carcinoma (SCC). We evaluated definitive CCRT failure patterns and determined the predictive factors for treatment response in esophageal SCC.
METHODS: We evaluated 136 consecutive patients with esophageal SCC treated with definitive CCRT. We evaluated the factors associated with complete remission (CR) after CCRT and analyzed the pattern of treatment failure of recurred patients and incomplete remission patients. The failures were categorized as either within (locoregional failure) or outside the radiation field (out-field failure).
RESULTS: Fifty-seven patients achieved CR after CCRT. Consolidation chemotherapy was significantly associated with CR. Only 4 (7.0%) patients had CR after CCRT in patients with M1a node (Celiac or subclavian lymph nodes involvement by 6th AJCC). During follow-up, 74 patients (54.4%) experienced locoregional failure, 26 (19.1%) out-field failure, and 35 (25.7%) no failure. Esophageal obstruction prior to CCRT, residual tumor according to the first follow-up endoscopy, and poor follow-up computed tomography responses were significantly associated with locoregional failure.
CONCLUSION: Approximately 70% of treatment failures were local failures. Future therapeutic strategies need to focus on improving local control to increase treatment outcomes of CCRT.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25531173     DOI: 10.1159/000368983

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  7 in total

1.  Treatment outcomes according to the macroscopic tumor type in locally advanced esophageal squamous cell carcinoma treated by chemoradiotherapy.

Authors:  Katsumaro Kubo; Koichi Wadasaki; Katsunori Shinozaki
Journal:  Jpn J Radiol       Date:  2019-01-28       Impact factor: 2.374

2.  Efficacy of Endoscopic Evaluation of Acute Radiation Esophagitis during Chemoradiotherapy with Proton Beam Therapy Boost for Esophageal Cancer.

Authors:  Kenkei Hasatani; Hiroyasu Tamamura; Kazutaka Yamamoto; Hiroyuki Aoyagi; Tamon Miyanaga; Yasuharu Kaizaki; Takeshi Sawada
Journal:  Digestion       Date:  2019-05-08       Impact factor: 3.216

3.  Predictors of post-treatment stenosis in cervical esophageal cancer undergoing high-dose radiotherapy.

Authors:  Jun Won Kim; Tae Hyung Kim; Jie-Hyun Kim; Ik Jae Lee
Journal:  World J Gastroenterol       Date:  2018-02-21       Impact factor: 5.742

4.  What is the optimal radiation dose for non-operable esophageal cancer? Dissecting the evidence in a meta-analysis.

Authors:  Yong Chen; Hui-Ping Zhu; Tao Wang; Chang-Jiang Sun; Xiao-Lin Ge; Ling-Feng Min; Xian-Wen Zhang; Qing-Qing Jia; Jie Yu; Jian-Qi Yang; Heike Allgayer; Mohammed L Abba; Xi-Zhi Zhang; Xin-Chen Sun
Journal:  Oncotarget       Date:  2017-06-28

5.  Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.

Authors:  Zongxing Zhao; Yanan Zhang; Xin Wang; Xiaotao Geng; Liqiong Zhu; Minghuan Li
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

6.  A re-irradiation dose of 55-60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy.

Authors:  Xun Wu; Xingsheng Hu; Junru Chen; Lang He
Journal:  Radiat Oncol       Date:  2021-06-08       Impact factor: 3.481

7.  Radiotherapy Combined With Concurrent Nedaplatin-Based Chemotherapy for Stage II-III Esophageal Squamous Cell Carcinoma.

Authors:  Huiping Zhu; Xiaoling Lu; Jian Jiang; Jingfeng Lu; Xinchen Sun; Yun Zuo
Journal:  Dose Response       Date:  2022-03-03       Impact factor: 2.658

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.